T Cell-Mediated Autoimmunity in Glaucoma Neurodegeneration

Area of Science:

• Ophthalmology
• Neuroimmunology
• Neurodegeneration

Background:

• Glaucoma is a primary cause of irreversible blindness, affecting millions worldwide.
• Current treatments focus on intraocular pressure (IOP) control, but evidence suggests immune-mediated damage to retinal ganglial cells (RGCs) plays a key role, potentially independent of IOP.
• Pathological mechanisms in glaucoma share similarities with central nervous system (CNS) neurodegenerative diseases like Alzheimer's and Parkinson's.

Purpose of the Study:

• To review the role of T cell-mediated immunity in glaucoma pathogenesis.
• To explore how findings from CNS neurodegenerative diseases can inform glaucoma research and treatment.

Main Methods:

• Literature review focusing on T cell-mediated immunity in glaucoma.
• Comparative analysis of pathological pathways in glaucoma and CNS neurodegenerative diseases.
• Exploration of immune modulation therapies.

Main Results:

• Accumulating evidence suggests T cells are central to the immune-mediated attack on the neural retina in glaucoma.
• Autoimmune aspects and T cell involvement in glaucoma mirror those observed in other CNS neurodegenerative conditions.
• Immune modulation therapies are showing promise in CNS diseases and may be applicable to glaucoma.

Conclusions:

• T cell-mediated immunity is a critical factor in glaucoma pathogenesis.
• Insights from neurodegenerative disease research, particularly regarding T cell immunity and treatments, offer promising avenues for future glaucoma research and therapeutic development.